Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
Better therapies for children: a worldwide search for needed human resources.

Paediatric drugs

MacLeod SM.
PMID: 25956169
Paediatr Drugs. 2015 Jun;17(3):175-7. doi: 10.1007/s40272-015-0132-6.

A point has been reached in the pursuit of optimal prescribing for infants, children and youth where global deficiencies in inter-professional communication are presenting a substantial barrier to progress. In an effort to remedy this situation, the International Alliance...

Cite
MacLeod SM. Better therapies for children: a worldwide search for needed human resources. Paediatr Drugs. 2015;17(3):175-7doi: 10.1007/s40272-015-0132-6.
MacLeod, S. M. (2015). Better therapies for children: a worldwide search for needed human resources. Paediatric drugs, 17(3), 175-7. https://doi.org/10.1007/s40272-015-0132-6
MacLeod, Stuart M. "Better therapies for children: a worldwide search for needed human resources." Paediatric drugs vol. 17,3 (2015): 175-7. doi: https://doi.org/10.1007/s40272-015-0132-6
MacLeod SM. Better therapies for children: a worldwide search for needed human resources. Paediatr Drugs. 2015 Jun;17(3):175-7. doi: 10.1007/s40272-015-0132-6. PMID: 25956169.
Copy Download .nbib Format: NLM
Epidemiology and management options for colorectal cancer in children.

Paediatric drugs

Saab R, Furman WL.
PMID: 18454570
Paediatr Drugs. 2008;10(3):177-92. doi: 10.2165/00148581-200810030-00006.

Colorectal carcinoma (CRC), although primarily a disease of adulthood, accounts for 2% of malignancies in adolescents and has been reported in children as young as 9 months of age. Our knowledge of CRC in pediatrics is based on a...

Cite
Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs. 2008;10(3):177-92doi: 10.2165/00148581-200810030-00006.
Saab, R., & Furman, W. L. (2008). Epidemiology and management options for colorectal cancer in children. Paediatric drugs, 10(3), 177-92. https://doi.org/10.2165/00148581-200810030-00006
Saab, Raya, and Furman, Wayne L. "Epidemiology and management options for colorectal cancer in children." Paediatric drugs vol. 10,3 (2008): 177-92. doi: https://doi.org/10.2165/00148581-200810030-00006
Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs. 2008;10(3):177-92. doi: 10.2165/00148581-200810030-00006. PMID: 18454570.
Copy Download .nbib Format: NLM
Medications for premature neonates: healthcare considerations.

Paediatric drugs

Walti H.
PMID: 18590341
Paediatr Drugs. 2008;10(4):207-8. doi: 10.2165/00148581-200810040-00001.

No abstract available.

Cite
Walti H. Medications for premature neonates: healthcare considerations. Paediatr Drugs. 2008;10(4):207-8doi: 10.2165/00148581-200810040-00001.
Walti, H. (2008). Medications for premature neonates: healthcare considerations. Paediatric drugs, 10(4), 207-8. https://doi.org/10.2165/00148581-200810040-00001
Walti, Hervé. "Medications for premature neonates: healthcare considerations." Paediatric drugs vol. 10,4 (2008): 207-8. doi: https://doi.org/10.2165/00148581-200810040-00001
Walti H. Medications for premature neonates: healthcare considerations. Paediatr Drugs. 2008;10(4):207-8. doi: 10.2165/00148581-200810040-00001. PMID: 18590341.
Copy Download .nbib Format: NLM
Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews.

Paediatric drugs

Wasserman R, Bocian A, Harris D, Slora E.
PMID: 21351811
Paediatr Drugs. 2011 Apr 01;13(2):119-24. doi: 10.2165/11584240-000000000-00000.

BACKGROUND: The recently renewed Best Pharmaceuticals for Children and Pediatric Research Equity Acts (BPCA/PREA) have continued industry incentives and opportunities for pediatric drug trials (PDTs). However, there is no current assessment of the capacity to perform PDTs.OBJECTIVE: The aim...

Cite
Wasserman R, Bocian A, Harris D, et al. Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews. Paediatr Drugs. 2011;13(2):119-24doi: 10.2165/11584240-000000000-00000.
Wasserman, R., Bocian, A., Harris, D., & Slora, E. (2011). Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews. Paediatric drugs, 13(2), 119-24. https://doi.org/10.2165/11584240-000000000-00000
Wasserman, Richard, et al. "Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews." Paediatric drugs vol. 13,2 (2011): 119-24. doi: https://doi.org/10.2165/11584240-000000000-00000
Wasserman R, Bocian A, Harris D, Slora E. Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews. Paediatr Drugs. 2011 Apr 01;13(2):119-24. doi: 10.2165/11584240-000000000-00000. PMID: 21351811.
Copy Download .nbib Format: NLM
Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials.

Paediatric drugs

Abdel-Rahman SM.
PMID: 31313103
Paediatr Drugs. 2019 Aug;21(4):205-214. doi: 10.1007/s40272-019-00347-5.

Individuals approached to participate in human subjects research, irrespective of age, must be completely apprised of the study, and researchers must ensure that the information is understood to the fullest extent possible, prior to decision making. However, evolving regulatory...

Cite
Abdel-Rahman SM. Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials. Paediatr Drugs. 2019;21(4):205-214doi: 10.1007/s40272-019-00347-5.
Abdel-Rahman, S. M. (2019). Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials. Paediatric drugs, 21(4), 205-214. https://doi.org/10.1007/s40272-019-00347-5
Abdel-Rahman, Susan M. "Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials." Paediatric drugs vol. 21,4 (2019): 205-214. doi: https://doi.org/10.1007/s40272-019-00347-5
Abdel-Rahman SM. Facilitating Informed Permission/Assent/Consent in Pediatric Clinical Trials. Paediatr Drugs. 2019 Aug;21(4):205-214. doi: 10.1007/s40272-019-00347-5. PMID: 31313103.
Copy Download .nbib Format: NLM
Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children.

Paediatric drugs

Hirsch S, Nurko S, Mitchell P, Rosen R.
PMID: 34950991
Paediatr Drugs. 2022 Jan;24(1):73-81. doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23.

BACKGROUND: Upper gastrointestinal (GI) symptoms are common in pediatrics, and few prokinetics for children exist. The goal of this study was to determine the efficacy of prucalopride for treatment of upper GI symptoms and feeding difficulties in children.METHODS: This...

Cite
Hirsch S, Nurko S, Mitchell P, et al. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2021;24(1):73-81doi: 10.1007/s40272-021-00489-5.
Hirsch, S., Nurko, S., Mitchell, P., & Rosen, R. (2022). Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatric drugs, 24(1), 73-81. https://doi.org/10.1007/s40272-021-00489-5
Hirsch, Suzanna, et al. "Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children." Paediatric drugs vol. 24,1 (2022): 73-81. doi: https://doi.org/10.1007/s40272-021-00489-5
Hirsch S, Nurko S, Mitchell P, Rosen R. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2022 Jan;24(1):73-81. doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23. PMID: 34950991.
Copy Download .nbib Format: NLM
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

Paediatric drugs

Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA.
PMID: 34904182
Paediatr Drugs. 2022 Jan;24(1):13-27. doi: 10.1007/s40272-021-00484-w. Epub 2021 Dec 13.

Pediatric antiphospholipid syndrome (APS) is a rare acquired multisystem autoimmune thromboinflammatory condition characterized by thrombotic and non-thrombotic clinical manifestations. APS in children and adolescents typically presents with large-vessel thrombosis, thrombotic microangiopathy, and, rarely, obstetric morbidity. Non-thrombotic clinical manifestations are...

Cite
Islabão AG, Trindade VC, da Mota LMH, et al. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs. 2021;24(1):13-27doi: 10.1007/s40272-021-00484-w.
Islabão, A. G., Trindade, V. C., da Mota, L. M. H., Andrade, D. C. O., & Silva, C. A. (2022). Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric drugs, 24(1), 13-27. https://doi.org/10.1007/s40272-021-00484-w
Islabão, Aline Garcia, et al. "Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects." Paediatric drugs vol. 24,1 (2022): 13-27. doi: https://doi.org/10.1007/s40272-021-00484-w
Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs. 2022 Jan;24(1):13-27. doi: 10.1007/s40272-021-00484-w. Epub 2021 Dec 13. PMID: 34904182; PMCID: PMC8667978.
Copy Download .nbib Format: NLM
Medical Management of Infantile Hemangiomas: An Update.

Paediatric drugs

Colmant C, Powell J.
PMID: 34677814
Paediatr Drugs. 2022 Jan;24(1):29-43. doi: 10.1007/s40272-021-00477-9. Epub 2021 Oct 22.

Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, affecting about 5% of infants. It has a characteristic growth pattern of early rapid proliferation followed by progressive involution. Although most IH evolve favorably, complications are observed...

Cite
Colmant C, Powell J. Medical Management of Infantile Hemangiomas: An Update. Paediatr Drugs. 2021;24(1):29-43doi: 10.1007/s40272-021-00477-9.
Colmant, C., & Powell, J. (2022). Medical Management of Infantile Hemangiomas: An Update. Paediatric drugs, 24(1), 29-43. https://doi.org/10.1007/s40272-021-00477-9
Colmant, Caroline, and Powell, Julie. "Medical Management of Infantile Hemangiomas: An Update." Paediatric drugs vol. 24,1 (2022): 29-43. doi: https://doi.org/10.1007/s40272-021-00477-9
Colmant C, Powell J. Medical Management of Infantile Hemangiomas: An Update. Paediatr Drugs. 2022 Jan;24(1):29-43. doi: 10.1007/s40272-021-00477-9. Epub 2021 Oct 22. PMID: 34677814.
Copy Download .nbib Format: NLM
Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children.

Paediatric drugs

Hirsch S, Nurko S, Mitchell P, Rosen R.
PMID: 34950991
Paediatr Drugs. 2021 Dec 23; doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23.

BACKGROUND: Upper gastrointestinal (GI) symptoms are common in pediatrics, and few prokinetics for children exist. The goal of this study was to determine the efficacy of prucalopride for treatment of upper GI symptoms and feeding difficulties in children.METHODS: This...

Cite
Hirsch S, Nurko S, Mitchell P, et al. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2021;doi: 10.1007/s40272-021-00489-5.
Hirsch, S., Nurko, S., Mitchell, P., & Rosen, R. (2021). Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatric drugs, . https://doi.org/10.1007/s40272-021-00489-5
Hirsch, Suzanna, et al. "Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children." Paediatric drugs vol. (2021). doi: https://doi.org/10.1007/s40272-021-00489-5
Hirsch S, Nurko S, Mitchell P, Rosen R. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2021 Dec 23; doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23. PMID: 34950991.
Copy Download .nbib Format: NLM
Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children.

Paediatric drugs

Hirsch S, Nurko S, Mitchell P, Rosen R.
PMID: 34950991
Paediatr Drugs. 2021 Dec 23; doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23.

BACKGROUND: Upper gastrointestinal (GI) symptoms are common in pediatrics, and few prokinetics for children exist. The goal of this study was to determine the efficacy of prucalopride for treatment of upper GI symptoms and feeding difficulties in children.METHODS: This...

Cite
Hirsch S, Nurko S, Mitchell P, et al. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2021;doi: 10.1007/s40272-021-00489-5.
Hirsch, S., Nurko, S., Mitchell, P., & Rosen, R. (2021). Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatric drugs, . https://doi.org/10.1007/s40272-021-00489-5
Hirsch, Suzanna, et al. "Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children." Paediatric drugs vol. (2021). doi: https://doi.org/10.1007/s40272-021-00489-5
Hirsch S, Nurko S, Mitchell P, Rosen R. Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children. Paediatr Drugs. 2021 Dec 23; doi: 10.1007/s40272-021-00489-5. Epub 2021 Dec 23. PMID: 34950991.
Copy Download .nbib Format: NLM
Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group.

Paediatric drugs

Dipasquale V, Martinelli M, Aloi M, Accomando S, Alvisi P, Arrigo S, Banzato C, Bramuzzo M, Cananzi M, Corpino M, Di Mari C, Di Nardo G, Dilillo A, Dodaro N, Felici E, Gatti S, Graziano F, Illiceto MT, Norsa L, Opramolla A, Pastore M, Pavanello PM, Romeo E, Scarallo L, Strisciuglio C, Zuin G, Romano C.
PMID: 34914084
Paediatr Drugs. 2021 Dec 16; doi: 10.1007/s40272-021-00486-8. Epub 2021 Dec 16.

OBJECTIVE: The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP).METHODS: An anonymous web survey involving all SIGENP...

Cite
Dipasquale V, Martinelli M, Aloi M, et al. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group. Paediatr Drugs. 2021;doi: 10.1007/s40272-021-00486-8.
Dipasquale, V., Martinelli, M., Aloi, M., Accomando, S., Alvisi, P., Arrigo, S., Banzato, C., Bramuzzo, M., Cananzi, M., Corpino, M., Di Mari, C., Di Nardo, G., Dilillo, A., Dodaro, N., Felici, E., Gatti, S., Graziano, F., Illiceto, M. T., Norsa, L., Opramolla, A., Pastore, M., Pavanello, P. M., Romeo, E., Scarallo, L., Strisciuglio, C., Zuin, G., & Romano, C. (2021). Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group. Paediatric drugs, . https://doi.org/10.1007/s40272-021-00486-8
Dipasquale, Valeria, et al. "Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group." Paediatric drugs vol. (2021). doi: https://doi.org/10.1007/s40272-021-00486-8
Dipasquale V, Martinelli M, Aloi M, Accomando S, Alvisi P, Arrigo S, Banzato C, Bramuzzo M, Cananzi M, Corpino M, Di Mari C, Di Nardo G, Dilillo A, Dodaro N, Felici E, Gatti S, Graziano F, Illiceto MT, Norsa L, Opramolla A, Pastore M, Pavanello PM, Romeo E, Scarallo L, Strisciuglio C, Zuin G, Romano C. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group. Paediatr Drugs. 2021 Dec 16; doi: 10.1007/s40272-021-00486-8. Epub 2021 Dec 16. PMID: 34914084.
Copy Download .nbib Format: NLM
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

Paediatric drugs

Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA.
PMID: 34904182
Paediatr Drugs. 2021 Dec 13; doi: 10.1007/s40272-021-00484-w. Epub 2021 Dec 13.

Pediatric antiphospholipid syndrome (APS) is a rare acquired multisystem autoimmune thromboinflammatory condition characterized by thrombotic and non-thrombotic clinical manifestations. APS in children and adolescents typically presents with large-vessel thrombosis, thrombotic microangiopathy, and, rarely, obstetric morbidity. Non-thrombotic clinical manifestations are...

Cite
Islabão AG, Trindade VC, da Mota LMH, et al. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs. 2021;doi: 10.1007/s40272-021-00484-w.
Islabão, A. G., Trindade, V. C., da Mota, L. M. H., Andrade, D. C. O., & Silva, C. A. (2021). Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric drugs, . https://doi.org/10.1007/s40272-021-00484-w
Islabão, Aline Garcia, et al. "Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects." Paediatric drugs vol. (2021). doi: https://doi.org/10.1007/s40272-021-00484-w
Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs. 2021 Dec 13; doi: 10.1007/s40272-021-00484-w. Epub 2021 Dec 13. PMID: 34904182; PMCID: PMC8667978.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries